Earnings
Novocure's Pancreatic Device Ends Quarter With 276 Patients And $3.7 Million In Sales As Rival Drug Crowds Clinics
CEO Frank Leonard says practices swamped by a rival's launch limit access for Optune Pax, and Novocure plans two small KRAS-inhibitor trials.